Scalper1 News
Wall Street analysts lowered the odds of success for BioMarin Pharmaceuticals’ (BMRN) muscular-dystrophy drug drisapersen on Wednesday in the wake of the FDA advisory committee vote late Tuesday. They delivered more mixed opinions on the implications for rivals Sarepta Therapeutics (SRPT) and PTC Therapeutics (PTCT). The FDA panel gave largely negative opinions of BioMarin’s drisapersen, or Kyndrisa, despite BioMarin’s assertion that the totality Scalper1 News
Scalper1 News